Interleukin-6 Promoter −174G/C Polymorphism and Hypertension: A Case–control Study and a Meta-Analysis
Wenquan Niu,Yue Qi,Pingjin Gao,Dingliang Zhu
DOI: https://doi.org/10.1016/j.ijcard.2009.09.246
IF: 4.039
2009-01-01
International Journal of Cardiology
Abstract:One promoter polymorphism, −174G/C, in interleukin-6 gene attracts special attention for its involvement in regulating transcription and association with hypertension by several studies. We first performed a case–control study investigating the association of this polymorphism with essential hypertension among Han Chinese (475 cases and 475 controls, matched for age and gender) from Shanghai, and then meta-analyzed all available evidence. Genotyping was done using PCR-RFLP techniques. Three genetic modes of inheritance were explored. As for meta-analysis, fixed-effects model was applied to pool data in the absence of between-studies heterogeneity, and random-effects model otherwise. Data and study quality were assessed in duplicate. Publication bias was evaluated using the fail-safe number. Our case–control study showed significant differences in the genotype/allele distributions of −174G/C polymorphism, and significance persisted under both additive and dominant modes. The following meta-analysis involving 1153 cases and 1291 controls supported the protective role of −174C allele (OR=0.77; 95% CI, 0.58 to 1.00; P=0.05), in line with the represent case–control results. In addition, significance was noted for the dominant effect (OR=0.69; 95% CI, 0.49 to 0.97; P<0.0001) rather than the recessive effect (OR=0.80; 95% CI, 0.56 to 1.13; P=0.20). The fail-safe number at the level of 0.05 was in favor of this positive association. Taken together, our case–control study and meta-analysis consistently support that the −174C allele was associated with a decreased risk to develop hypertension and this effect appeared to manifest in a dominant action. One promoter polymorphism, −174G/C, in interleukin-6 gene attracts special attention for its involvement in regulating transcription and association with hypertension by several studies. We first performed a case–control study investigating the association of this polymorphism with essential hypertension among Han Chinese (475 cases and 475 controls, matched for age and gender) from Shanghai, and then meta-analyzed all available evidence. Genotyping was done using PCR-RFLP techniques. Three genetic modes of inheritance were explored. As for meta-analysis, fixed-effects model was applied to pool data in the absence of between-studies heterogeneity, and random-effects model otherwise. Data and study quality were assessed in duplicate. Publication bias was evaluated using the fail-safe number. Our case–control study showed significant differences in the genotype/allele distributions of −174G/C polymorphism, and significance persisted under both additive and dominant modes. The following meta-analysis involving 1153 cases and 1291 controls supported the protective role of −174C allele (OR=0.77; 95% CI, 0.58 to 1.00; P=0.05), in line with the represent case–control results. In addition, significance was noted for the dominant effect (OR=0.69; 95% CI, 0.49 to 0.97; P<0.0001) rather than the recessive effect (OR=0.80; 95% CI, 0.56 to 1.13; P=0.20). The fail-safe number at the level of 0.05 was in favor of this positive association. Taken together, our case–control study and meta-analysis consistently support that the −174C allele was associated with a decreased risk to develop hypertension and this effect appeared to manifest in a dominant action.